Business Context and Reporting Period
This Form 6-K filing covers the month of November 2009 for Prana Biotechnology Limited (ASX Code: PBT), a foreign private issuer based in Australia. The filing serves as a notice under Section 708A(5) of the Corporations Act regarding the issuance of securities without prior disclosure to investors under Part 6D.2.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes via security issuance.
| Security Type | Quantity Issued | Issue Price | Key Terms |
|---|---|---|---|
| Ordinary Fully Paid Shares | 750,000 | AUD $0.00 | Issued Nov 27, 2009 |
| Unlisted Options (Class 1) | 10,000,000 | AUD $0.00 | Strike: AUD $0.30; Expiry: Sept 11, 2013 |
| Unlisted Options (Class 2) | 3,500,000 | AUD $0.00 | Strike: AUD $0.30; Expiry: Sept 23, 2012 |
Material Changes
The primary material change is the issuance of 750,000 ordinary shares and 13.5 million unlisted options on November 27, 2009. All securities were issued at a price of AUD $0.00. The company intends to apply to the Australian Stock Exchange for quotation of the newly issued shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies are detailed beyond the regulatory requirement to disclose the issuance of securities without a prospectus. The company confirms compliance with Chapter 2M and Section 674 of the Corporations Act.
Investor Verification Checklist
- Verify the total number of shares outstanding post-issuance to assess dilution impact.
- Confirm the identity of the recipients of the 13.5 million options and the 750,000 shares.
- Check the Australian Stock Exchange (ASX) for the approval status of the quotation application for the new shares.
- Review the company's capital raising history to understand the context of issuing securities at nil consideration.